1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Procardia® XL (Nifedipine) tablets

Trade Name: Procardia; Procardia XL

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product for the treatment of high blood pressure (hypertension), angina

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
International CHEMTREC (24 hours): +1-703-527-3887

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

Label Elements

Signal Word: Not Classified

Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
</table>
3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ferric oxide red</td>
<td>1309-37-1</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Nifedipine</td>
<td>21829-25-4</td>
<td>244-598-3</td>
<td>Acute tox.4 (H302)</td>
<td>11</td>
</tr>
<tr>
<td>Polyethylene glycol</td>
<td>25322-68-3</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>7647-14-5</td>
<td>231-598-3</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Titanium dioxide</td>
<td>13463-67-7</td>
<td>236-675-5</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information:  
* Proprietary 
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact:  Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact:  Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion:  Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation:  Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure:  For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure:  None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician:  None

5. FIRE FIGHTING MEASURES

Extinguishing Media:  Use carbon dioxide, dry chemical, or water spray.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products:  Emits toxic fumes of carbon monoxide, carbon dioxide, and nitrogen oxides.

Fire / Explosion Hazards:  Not applicable
Advice for Fire-Fighters
During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities
Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.

Ferric oxide red
ACGIH Threshold Limit Value (TWA) 5 mg/m³
Australia TWA 5 mg/m³
Austria OEL - MAKs 5 mg/m³
Belgium OEL - TWA 10 mg/m³
Bulgaria OEL - TWA 5.0 mg/m³
Denmark OEL - TWA 3.5 mg/m³
Estonia OEL - TWA 3.5 mg/m³
Finland OEL - TWA 5 mg/m³
France OEL - TWA 5 mg/m³
Greece OEL - TWA 10 mg/m³
Hungary OEL - TWA 6 mg/m³
### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

<table>
<thead>
<tr>
<th>Material Name</th>
<th>TWA Concentration (mg/m³)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Polyethylene glycol</strong></td>
<td></td>
</tr>
<tr>
<td>Austria OEL - MAKs</td>
<td>1000 mg/m³</td>
</tr>
<tr>
<td>Germany - TRGS 900 - TWAs</td>
<td>1000 mg/m³</td>
</tr>
<tr>
<td>Germany (DFG) - MAK</td>
<td>1000 mg/m³ average molecular weight 200-600</td>
</tr>
<tr>
<td>Slovakia OEL - TWA</td>
<td>1000 mg/m³</td>
</tr>
<tr>
<td>Slovenia OEL - TWA</td>
<td>1000 mg/m³</td>
</tr>
<tr>
<td>Switzerland OEL - TWAs</td>
<td>1000 mg/m³</td>
</tr>
<tr>
<td><strong>Polyethylene oxide NF</strong></td>
<td></td>
</tr>
<tr>
<td>Austria OEL - MAKs</td>
<td>1000 mg/m³</td>
</tr>
<tr>
<td>Germany - TRGS 900 - TWAs</td>
<td>1000 mg/m³</td>
</tr>
<tr>
<td>Germany (DFG) - MAK</td>
<td>1000 mg/m³ average molecular weight 200-600</td>
</tr>
<tr>
<td>Slovakia OEL - TWA</td>
<td>1000 mg/m³</td>
</tr>
<tr>
<td>Slovenia OEL - TWA</td>
<td>1000 mg/m³</td>
</tr>
<tr>
<td>Switzerland OEL - TWAs</td>
<td>1000 mg/m³</td>
</tr>
<tr>
<td><strong>Sodium chloride</strong></td>
<td></td>
</tr>
<tr>
<td>Latvia OEL - TWA</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Lithuania OEL - TWA</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td><strong>Titanium dioxide</strong></td>
<td></td>
</tr>
<tr>
<td>ACGIH Threshold Limit Value (TWA)</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Australia TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Austria OEL - MAKs</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Belgium OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Bulgaria OEL - TWA</td>
<td>10.0 mg/m³</td>
</tr>
<tr>
<td>Denmark OEL - TWA</td>
<td>6 mg/m³</td>
</tr>
<tr>
<td>Estonia OEL - TWA</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>France OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
</tbody>
</table>

---

**Notes:**
- Polyethylene glycol and polyethylene oxide NF have TWA concentrations of 1000 mg/m³, with the exception of the German MAK values for the former, which is 5 mg/m³.
- The TWA concentration for Sodium chloride is 5 mg/m³ for both Latvia and Lithuania.
- Titanium dioxide has ACGIH and ACGIH MAK values, with varying concentrations for different countries.
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Exposure Controls

Engineering Controls:
Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:
Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands:
Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes:
Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin:
Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection:
Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN149, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Tablet
Odor: No data available.
Molecular Formula: Mixture
Solvent Solubility: No data available
Water Solubility: No data available.

Color: Rose-pink
Odor Threshold: No data available.
Molecular Weight: Mixture
9. PHYSICAL AND CHEMICAL PROPERTIES

Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.
Partition Coefficient: (Method, pH, Endpoint, Value) No data available.
Polyethylene oxide NF No data available
Hydroxypropyl methylcellulose No data available
Magnesium stearate No data available
Ferric oxide red No data available
Nifedipine Measured N/A Log P 2.20
Cellulose acetate No data available
Hydroxypropyl cellulose No data available
Titanium dioxide No data available
Sodium chloride No data available
Polyethylene glycol No data available
Decomposition Temperature (°C): No data available.
Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available
Flammability:
  Autoignition Temperature (Solid) (°C): No data available
  Flammability (Solids): No data available
  Flash Point (Liquid) (°C): No data available
  Upper Explosive Limits (Liquid) (% by Vol.): No data available
  Lower Explosive Limits (Liquid) (% by Vol.): No data available
Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
  Oxidizing Properties: No data available
  Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
  Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
  Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Short Term: Dust may cause irritation. May be harmful if swallowed. Individuals sensitive to this chemical or other materials in its chemical class may develop allergic reactions. Exposure to sunlight following contact may result in skin reactions. Antihypertensive drug: has blood pressure-lowering properties

Known Clinical Effects: Adverse effects associated with therapeutic use include decrease in blood pressure (hypotension), headache, dizziness, fatigue, drowsiness, constipation, nausea, gastrointestinal perforation and ulceration.

Acute Toxicity: (Species, Route, End Point, Dose)

Hydroxypropyl methylcellulose
Rat Oral LD50 > 10,000 mg/kg

Magnesium stearate
Rat Oral LD50 > 2000 mg/kg
Rat Inhalation LC50 > 2000 mg/m³

Nifedipine
Mouse Oral LD50 454 mg/kg
Rat Oral LD50 1022mg/kg
Mouse IV LD50 4.2mg/kg
Rat IV LD50 15.5mg/kg

Titanium dioxide
Rat Oral LD50 > 7500 mg/kg
Rat Subcutaneous LD50 50 mg/kg

Sodium chloride
Rat Oral LD50 3000 mg/kg
Mouse Oral LD50 4000 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Polyethylene oxide NF
Eye Irritation Rabbit Mild
Skin Irritation Rabbit Mild

Sodium chloride
Eye Irritation Rabbit Moderate
Skin Irritation Rabbit Mild

Polyethylene glycol
Eye Irritation Rabbit Mild
Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)
11. TOXICOLOGICAL INFORMATION

Nifedipine
13 Week(s) Rat Oral 100 mg/kg/day NOAEL No effects at maximum dose
13 Week(s) Dog Oral 50 mg/kg/day NOAEL No effects at maximum dose
4 Week(s) Dog Oral 125 mg/kg/day NOAEL No effects at maximum dose
4 Week(s) Dog Intravenous 0.6 mg/kg/day NOAEL No effects at maximum dose
1 Year(s) Dog Oral 100 mg/kg/day NOAEL No effects at maximum dose

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Nifedipine
Reproductive & Fertility Rat Oral 3 mg/kg/day NOAEL Reproductive toxicity, Embryotoxicity, Postnatal mortality, Maternal toxicity
Peri-/Postnatal Development Rat Oral 4 mg/kg/day NOAEL Reproductive toxicity, Fetotoxicity, Maternal Toxicity
Peri-/Postnatal Development Rat Oral 3 mg/kg/day NOAEL Embryotoxicity
Embryo / Fetal Development Rat Oral 10 mg/kg/day NOAEL Maternal Toxicity, Fetotoxicity, Developmental toxicity
Embryo / Fetal Development Rabbit Oral 10 mg/kg/day LOAEL Developmental toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Nifedipine
In Vivo Dominant Lethal Assay Mouse Negative
In Vivo Cytogenetics Hamster Negative
In Vivo Micronucleus Mouse Negative
Bacterial Mutagenicity (Ames) Salmonella Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Nifedipine
2 Year(s) Rat Oral 156-210 mg/kg/day NOAEL Not carcinogenic

Carcinogen Status:
None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

Ferric oxide red
IARC: Group 3 (Not Classifiable)

Titanium dioxide
IARC: Group 2B (Possibly Carcinogenic to Humans)

12. ECOLOGICAL INFORMATION

Environmental Overview:
The environmental characteristics of this mixture have not been fully evaluated. Releases to the environment should be avoided.

Toxicity:
Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Nifedipine
Brachydanio rerio (Zebra fish) LC50 96 Hours > 5.77 mg/L
Daphnia magna (Water Flea) EC50 48 Hours > 3.88 mg/L
Aquatic Toxicity Comments: A greater than symbol (>) indicates that aquatic toxicity was not observed at the maximum dose tested.

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

<table>
<thead>
<tr>
<th>Substance</th>
<th>Inoculum</th>
<th>Method</th>
<th>End Point</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nifedipine</td>
<td>Activated sludge</td>
<td>EC50</td>
<td>&gt; 10000 mg/L</td>
<td></td>
</tr>
</tbody>
</table>

Persistence and Degradability: No data available

Bio-accumulative Potential:

<table>
<thead>
<tr>
<th>Substance</th>
<th>Method, pH, Endpoint, Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nifedipine</td>
<td>Measured N/A Log P 2.20</td>
</tr>
</tbody>
</table>

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Cellulose acetate
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
## 15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>Material</th>
<th>EU EINECS/ELINCS List</th>
<th>Not Listed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Magnesium stearate</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
<td></td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
<td></td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>215-168-2</td>
<td></td>
</tr>
</tbody>
</table>

| Hydroxypropyl cellulose   |                       |             |
| CERCLA/SARA 313 Emission reporting | Not Listed    |             |
| California Proposition 65 | Not Listed          |             |
| Inventory - United States TSCA - Sect. 8(b) | Present   |             |
| Australia (AICS):         | Present             |             |
| EU EINECS/ELINCS List     | Not Listed          |             |

| Hydroxypropyl methylcellulose |                       |             |
| CERCLA/SARA 313 Emission reporting | Not Listed    |             |
| California Proposition 65     | Not Listed         |             |
| Inventory - United States TSCA - Sect. 8(b) | Present   |             |
| Australia (AICS):             | Present             |             |
| Standard for the Uniform Scheduling for Drugs and Poisons: | Schedule 4 |             |
| EU EINECS/ELINCS List         | Not Listed          |             |

| Nifedipine                  |                       |             |
| CERCLA/SARA 313 Emission reporting | Not Listed    |             |
| California Proposition 65    | Not Listed           |             |
| Inventory - United States TSCA - Sect. 8(b) | Present |             |
| Australia (AICS):            | Present             |             |
| Standard for the Uniform Scheduling for Drugs and Poisons: | Schedule 4 |             |
| EU EINECS/ELINCS List        | 244-598-3           |             |

| Polyethylene glycol         |                       |             |
| CERCLA/SARA 313 Emission reporting | Not Listed    |             |
| California Proposition 65    | Not Listed           |             |
| Inventory - United States TSCA - Sect. 8(b) | Present |             |
| Australia (AICS):            | Present             |             |
| Standard for the Uniform Scheduling for Drugs and Poisons: | Schedule 2 |             |
| EU EINECS/ELINCS List        | Schedule 3          |             |

| Polyethylene oxide NF       |                       |             |
| CERCLA/SARA 313 Emission reporting | Not Listed    |             |
15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>California Proposition 65</th>
<th>Inventory - United States TSCA - Sect. 8(b)</th>
<th>Australia (AICS):</th>
<th>Standard for the Uniform Scheduling</th>
<th>EU EINECS/ELINCS List</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium chloride</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td>Schedule 2</td>
<td>Not Listed</td>
</tr>
<tr>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>231-598-3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Titanium dioxide

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>California Proposition 65</th>
<th>Inventory - United States TSCA - Sect. 8(b)</th>
<th>Australia (AICS):</th>
<th>EU EINECS/ELINCS List</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>California Proposition 65</td>
<td>cancerogen 9/2/2011 airborne, unbound particles of respirable size</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>236-675-5</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 7 - Handling and Storage. Updated Section 3 - Composition / Information on Ingredients. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 12 - Ecological Information.

Revision date: 04-Oct-2018

Prepared by: Product Stewardship Hazard Communication

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet